GCT Development Centers | Academia’s Unique Contribution
Tuesday, May 3, 2022
This panel will examine the role of academia in driving the promise of GCT. How does academic innovation contribute to the success of GCT? What are the risks and opportunities? Which models have proven most successful and what is the impact on clinical translation? How can these partnerships be accelerated?
- Moderator:
-
- Ravi Thadhani, MD
-
- Chief Academic Officer, Mass General Brigham
- Panelists:
-
- Carl June, MD
-
- Richard W. Vague Professor in Immunotherapy, Director, Center for Cellular Immunotherapies, Director, Parker Institute for Cancer Immunotherapy, University of Pennsylvania Perelman School of Medicine
- Maria Millan, MD
-
- President & CEO, California Institute for Regenerative Medicine
- Richard Mulligan, PhD
-
- Mallinckrodt Professor of Genetics, Emeritus, HMS
- Executive Vice Chairman, Sana Biotechnology, Inc
- Norman Sharpless, MD
-
- Former Director, National Cancer Institute